MiR-497 Decreases Cisplatin Resistance in Ovarian Cancer Cells by Targeting MTOR/P70S6K1

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Aug 5

PMID 26238185

Citations 47

Authors

Shaohua Xu

Guang-Bo Fu

Zhen Tao

Jun Ouyang

Fanfei Kong

Bing-Hua Jiang

Xiaoping Wan

Ke Chen

Affiliations

Soon will be listed here.

Abstract

The mechanism of cisplatin resistance in ovarian cancer is not clearly understood. In the present investigation, we found that the expression levels of miR-497 were reduced in chemotherapy-resistant ovarian cancer cells and tumor tissues due to hypermethylation of miR-497 promoter. Low miR-497 expression levels were associated with chemo-resistant phonotype of ovarian cancer. By analyzing the expression levels of miR-497, mTOR and p70S6K1 in a clinical gene-expression array dataset, we found that mTOR and p70S6K1, two proteins correlated to chemotherapy-resistance in multiple types of human cancers, were inversely correlated with miR-497 levels in ovarian cancer tissues. By using an orthotopic ovarian tumor model and a Tet-On inducible miR-497 expression system, our results demonstrated that overexpression of miR-497 sensitizes the resistant ovarian tumor to cisplatin treatment. Therefore, we suggest that miR-497 might be used as a therapeutic supplement to increase ovarian cancer treatment response to cisplatin.

Citing Articles

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in -Mutated Epithelial Ovarian Cancer Cell Lines.

Gralewska P, Biegala L, Gajek A, Szymczak-Pajor I, Marczak A, Sliwinska A Int J Mol Sci. 2025; 26(2).

PMID: 39859407 PMC: 11766100. DOI: 10.3390/ijms26020693.

Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.

Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.

Alghamian Y, Soukkarieh C, Aljapawe A, Murad H Biochem Biophys Rep. 2025; 41():101906.

PMID: 39830525 PMC: 11741906. DOI: 10.1016/j.bbrep.2024.101906.

miR-497-5p Expression and Biological Activity in Gastric Cancer.

Chen X, Zhou L, Han Y, Lin S, Zhou L, Wang W J Cancer. 2024; 15(12):3995-4006.

PMID: 38911367 PMC: 11190777. DOI: 10.7150/jca.90087.

Current data and future perspectives on DNA methylation in ovarian cancer (Review).

Fu M, Deng F, Chen J, Fu L, Lei J, Xu T Int J Oncol. 2024; 64(6).

PMID: 38757340 PMC: 11095605. DOI: 10.3892/ijo.2024.5650.

References

Tanaka T, Bai T, Toujima S, Utsunomiya T, Matsuoka T, Kobayashi A . Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells. Oncol Rep. 2012; 27(4):1292-8. PMC: 3583479. DOI: 10.3892/or.2012.1628. View

Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y . Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011; 17(7):1722-30. DOI: 10.1158/1078-0432.CCR-10-1800. View

Marioni G, Staffieri A, Lora L, Fermo S, Giacomelli L, La Torre F . mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multivariate analyses. Oral Oncol. 2012; 48(6):530-4. DOI: 10.1016/j.oraloncology.2012.01.002. View

Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T . The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One. 2013; 8(3):e60155. PMC: 3609788. DOI: 10.1371/journal.pone.0060155. View

Guo S, Jiang C, Wang G, Li Y, Wang C, Guo X . MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 2012; 32(15):1910-20. PMC: 3630484. DOI: 10.1038/onc.2012.214. View

Luo M, Shen D, Zhou X, Chen X, Wang W . MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013; 153(6):836-47. DOI: 10.1016/j.surg.2012.12.004. View

Guo W, Zhang Y, Zhang L, Huang B, Tao F, Chen W . Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin. Autophagy. 2013; 9(7):996-1008. PMC: 3722334. DOI: 10.4161/auto.24407. View

Heavey S, OByrne K, Gately K . Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev. 2013; 40(3):445-56. DOI: 10.1016/j.ctrv.2013.08.006. View

Xu J, Wang T, You L, Zheng L, Shu H, Zhang T . Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer. PLoS One. 2014; 9(3):e92847. PMC: 3965476. DOI: 10.1371/journal.pone.0092847. View

10.

Xu S, Xu P, Wu W, Ou Y, Xu J, Zhang G . The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features. Curr Pharm Des. 2013; 20(11):1888-95. DOI: 10.2174/13816128113199990523. View

11.

Parkhitko A, Favorova O, Khabibullin D, Anisimov V, Henske E . Kinase mTOR: regulation and role in maintenance of cellular homeostasis, tumor development, and aging. Biochemistry (Mosc). 2014; 79(2):88-101. DOI: 10.1134/S0006297914020023. View

12.

Wang T, Liu Z, Guo S, Wu L, Li M, Yang J . The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget. 2014; 5(11):3611-21. PMC: 4116507. DOI: 10.18632/oncotarget.1968. View

13.

Xu J, Wang T, Cao Z, Huang H, Li J, Liu W . MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget. 2014; 5(16):6983-93. PMC: 4196178. DOI: 10.18632/oncotarget.2184. View

14.

Wang T, Guo S, Liu Z, Wu L, Li M, Yang J . CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. Oncotarget. 2014; 5(21):10293-306. PMC: 4279373. DOI: 10.18632/oncotarget.2511. View

15.

He J, Yu J, Xu Q, Wang L, Zheng J, Liu L . Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy. 2015; 11(2):373-84. PMC: 4502709. DOI: 10.1080/15548627.2015.1009781. View

16.

Greenlee R, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin. 2001; 51(1):15-36. DOI: 10.3322/canjclin.51.1.15. View

17.

Rauhut R, Lendeckel W, Tuschl T . Identification of novel genes coding for small expressed RNAs. Science. 2001; 294(5543):853-8. DOI: 10.1126/science.1064921. View

18.

Armstrong D . Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002; 7 Suppl 5:20-8. DOI: 10.1634/theoncologist.7-suppl_5-20. View

19.

Odunsi K, Jungbluth A, Stockert E, Qian F, Gnjatic S, Tammela J . NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003; 63(18):6076-83. View

20.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View